Madhya Pradesh Toxic Cough Syrup Child Deaths Case

In February 2025, multiple children in Madhya Pradesh's Ujjain district died after consuming contaminated cough syrup manufactured by Maiden Pharmaceuticals. The syrup contained toxic levels of diethylene glycol and ethylene glycol, industrial solvents used as cheaper alternatives to pharmaceutical-grade glycerin. Investigators traced the adulterated batch to a manufacturing plant in Haryana, revealing systemic quality control failures. The Central Drugs Standard Control Organization launched nationwide inspections, while the World Health Organization issued a global medical product alert. This incident mirrored the 2022 Gambia tragedy linked to the same company, raising concerns about India's pharmaceutical export regulations.

As of mid-2026, criminal investigations continue against company directors Naresh Kumar Goyal and Sharad Goyal for culpable homicide not amounting to murder under Indian Penal Code Section 304. Maiden Pharmaceuticals' manufacturing license remains suspended, with the Supreme Court monitoring the case.

Whether Maiden Pharmaceuticals knowingly used industrial-grade toxins as cost-cutting measures, and whether regulatory agencies failed to enforce safety protocols despite prior violations. The case highlighted the accountability gap between state and central drug regulators in monitoring manufacturing supply chains.

The tragedy triggered nationwide outrage over pharmaceutical safety, leading to mandatory glycerin purity testing protocols and stricter export quality checks. Parliament amended the Drugs and Cosmetics Act to enhance penalties for adulteration. India's reputation as the "world's pharmacy" faced international scrutiny, prompting diplomatic efforts to restore confidence in generic medicine exports.